Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DZ7OC3
|
|||
| Drug Name |
Iomab-ACT
|
|||
| Drug Type |
Antibody
|
|||
| Indication | B-cell acute lymphoblastic leukaemia [ICD-11: 2B33.3; ICD-10: C91, C91.9] | Phase 1 | [1] | |
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 1 | [1] | ||
| Company |
Actinium Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte common antigen (PTPRC) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Panther Pathway | B cell activation | |||
| JAK/STAT signaling pathway | ||||
| T cell activation | ||||
| Pathway Interaction Database | BCR signaling pathway | |||
| TCR signaling in naï | ||||
| TCR signaling in naï | ||||
| CXCR4-mediated signaling events | ||||
| Reactome | Phosphorylation of CD3 and TCR zeta chains | |||
| Other semaphorin interactions | ||||
| WikiPathways | Interferon type I signaling pathways | |||
| EPO Receptor Signaling | ||||
| B Cell Receptor Signaling Pathway | ||||
| TCR signaling | ||||
| Semaphorin interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04512716) Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Actinium Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.